Authors
Gerald F. Watts
David R. Sullivan
David L. Hare
Karam M. Kostner
Ari E. Horton
Damon A. Bell
Tom Brett
Ronald J. Trent
Nicola K. Poplawski
Andrew C. Martin
Shubha Srinivasan
Robert N. Justo
Clara K. Chow
Jing Pang
Zanfina Ademi
Justin J. Ardill
Wendy Barnett
Timothy R. Bates
Lawrence J. Beilin
Warrick Bishop
J. Andrew Black
Peter Brett
Alex Brown
John R. Burnett
Christina A. Bursill
Alison Colley
Peter M. Clifton
Elif I. Ekinci
Luke Elias
Gemma A. Figtree
Brett H. Forge
Jacquie Garton-Smith
Dorothy F. Graham
Ian Hamilton-Craig
Christian R. Hamilton-Craig
Clare Heal
Charlotte M. Hespe
Amanda J. Hooper
Laurence G. Howes
Jodie Ingles
John Irvin
Edward D. Janus
Nadarajah Kangaharan
Anthony C. Keech
Andrew B. Kirke
Leonard Kritharides
Campbell V. Kyle
Paul Lacaze
Kirsten Lambert, Edith Cowan UniversityFollow
Stephen C. H. Li
Wynand Malan
Stjepana Maticevic
Brendan M. McQuillan
Sam Mirzaee
Trevor A. Mori
Allison C. Morton
David M. Colquhoun
Joanna C. Moullin
Paul J. Nestel
Kristen J. Nowak
Richard C. O'Brien
Nicholas Pachter
Michael M. Page
Annette Pedrotti
Peter J. Psaltis
Jan Radford
Nicola J. Reid
Elizabeth N. Robertson
Jacqueline D. M. Ryan
Mitchell N. Sarkies
Carl J. Schultz
Russell S. Scott
Christopher Semsarian
Leon A. Simons
Catherine Spinks
Andrew M. Tonkin
Frank van Bockxmeer
Kathryn E. Waddell-Smith
Natalie C. Ward
Harvey D. White
Andrew M. Wilson
Ingrid Winship
Ann Marie Woodward
Stephen J. Nicholls
FH Australasia Network Consensus Working Group
Document Type
Journal Article
Publication Title
Heart, Lung and Circulation
Publisher
Elsevier
School
School of Education
RAS ID
36058
Funders
Raine Clinical Research Fellowship Western Australian Health Translation Network (WAHTN) Early Career Fellowship Australian Government's Medical Research Future Fund
Abstract
Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL)-cholesterol concentration and, if untreated, leads to premature atherosclerosis and coronary artery disease (CAD). There are approximately 100,000 people with FH in Australia. However, an overwhelming majority of those affected remain undetected and inadequately treated, consistent with FH being a leading challenge for public health genomics. To further address the unmet need, we provide an updated guidance, presented as a series of systematically collated recommendations, on the care of patients and families with FH. These recommendations have been informed by an exponential growth in published works and new evidence over the last 5 years and are compatible with a contemporary global call to action on FH. Recommendations are given on the detection, diagnosis, assessment and management of FH in adults and children. Recommendations are also made on genetic testing and risk notification of biological relatives who should undergo cascade testing for FH. Guidance on management is based on the concepts of risk re-stratification, adherence to heart healthy lifestyles, treatment of non-cholesterol risk factors, and safe and appropriate use of LDL-cholesterol lowering therapies, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein apheresis. Broad recommendations are also provided for the organisation and development of health care services. Recommendations on best practice need to be underpinned by good clinical judgment and shared decision making with patients and families. Models of care for FH need to be adapted to local and regional health care needs and available resources. A comprehensive and realistic implementation strategy, informed by further research, including assessments of cost-benefit, will be required to ensure that this new guidance benefits all Australian families with or at risk of FH.
DOI
10.1016/j.hlc.2020.09.943
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Watts, G. F., Sullivan, D. R., Hare, D. L., Kostner, K. M., Horton, A. E., Bell, D. A., ... Nicholls, S. J. (2021). Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia. Heart, Lung and Circulation, 30(3), 324-349. https://doi.org/10.1016/j.hlc.2020.09.943